|
1
|
Roberts LR: Sorafenib in liver cancer -
just the beginning. N Engl J Med. 359:420–422. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Murakami Y, Yasuda T, Saigo K, et al:
Comprehensive analysis of microRNA expression patterns in
hepatocellular carcinoma and non-tumorous tissues. Oncogene.
25:2537–2545. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Varnholt H, Drebber U, Schulze F, et al:
MicroRNA gene expression profile of hepatitis C virus-associated
hepatocellular carcinoma. Hepatology. 47:1223–1232. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Ji J, Shi J, Budhu A, et al: MicroRNA
expression, survival, and response to interferon in liver cancer. N
Engl J Med. 361:1437–1447. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Ladeiro Y, Couchy G, Balabaud C, et al:
MicroRNA profiling in hepatocellular tumors is associated with
clinical features and oncogene/tumor suppressor gene mutations.
Hepatology. 47:1955–1963. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Gramantieri L, Ferracin M, Fornari F, et
al: Cyclin G1 is a target of miR-122a, a microRNA frequently
down-regulated in human hepatocellular carcinoma. Cancer Res.
67:6092–6099. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Hou J, Lin L, Zhou W, et al:
Identification of miRNomes in human liver and hepatocellular
carcinoma reveals miR-199a/b-3p as therapeutic target for
hepatocellular carcinoma. Cancer Cell. 19:232–243. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Pineau P, Volinia S, McJunkin K, et al:
miR-221 overexpression contributes to liver tumorigenesis. Proc
Natl Acad Sci USA. 107:264–269. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Yuen MF, Wu PC, Lai VC, Lau JY and Lai CL:
Expression of c-Myc, c-Fos, and c-jun in hepatocellular carcinoma.
Cancer. 91:106–112. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Kawate S, Fukusato T, Ohwada S, Watanuki A
and Morishita Y: Amplification of c-myc in hepatocellular
carcinoma: correlation with clinicopathologic features,
proliferative activity and p53 overexpression. Oncology.
57:157–163. 1999.
|
|
11
|
Lin CP, Liu CR, Lee CN, Chan TS and Liu
HE: Targeting c-Myc as a novel approach for hepatocellular
carcinoma. World J Hepatol. 2:16–20. 2010.PubMed/NCBI
|
|
12
|
Suzuki H, Fujita H, Mullauer L, et al:
Increased expression of c-jun gene during spontaneous
hepatocarcinogenesis in LEC rats. Cancer Lett. 53:205–212. 1990.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Ye H, Liu X, Lv M, et al: MicroRNA and
transcription factor co-regulatory network analysis reveals miR-19
inhibits CYLD in T-cell acute lymphoblastic leukemia. Nucleic Acids
Res. 40:5201–5214. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Yu Z, Wang C, Wang M, et al: A cyclin
D1/microRNA 17/20 regulatory feedback loop in control of breast
cancer cell proliferation. J Cell Biol. 182:509–517. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Brosh R, Shalgi R, Liran A, et al:
p53-Repressed miRNAs are involved with E2F in a feed-forward loop
promoting proliferation. Mol Syst Biol. 4:2292008. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
He XX, Chang Y, Meng FY, et al:
MicroRNA-375 targets AEG-1 in hepatocellular carcinoma and
suppresses liver cancer cell growth in vitro and in vivo. Oncogene.
31:3357–3369. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Garofalo M, Di Leva G, Romano G, et al:
miR-221&222 regulate TRAIL resistance and enhance
tumorigenicity through PTEN and TIMP3 downregulation. Cancer Cell.
16:498–509. 2009. View Article : Google Scholar
|
|
18
|
le Sage C, Nagel R, Egan DA, et al:
Regulation of the p27Kip1 tumor suppressor by miR-221
and miR-222 promotes cancer cell proliferation. EMBO J.
26:3699–3708. 2007.
|
|
19
|
Ciafre SA, Galardi S, Mangiola A, et al:
Extensive modulation of a set of microRNAs in primary glioblastoma.
Biochem Biophys Res Commun. 334:1351–1358. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Lee EJ, Gusev Y, Jiang J, et al:
Expression profiling identifies microRNA signature in pancreatic
cancer. Int J Cancer. 120:1046–1054. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Gottardo F, Liu CG, Ferracin M, et al:
Micro-RNA profiling in kidney and bladder cancers. Urol Oncol.
25:387–392. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
He H, Jazdzewski K, Li W, et al: The role
of microRNA genes in papillary thyroid carcinoma. Proc Natl Acad
Sci USA. 102:19075–19080. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Chun-Zhi Z, Lei H, An-Ling Z, et al:
MicroRNA-221 and microRNA-222 regulate gastric carcinoma cell
proliferation and radioresistance by targeting PTEN. BMC Cancer.
10:3672010. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Sun K, Wang W, Zeng JJ, Wu CT, Lei ST and
Li GX: MicroRNA-221 inhibits CDKN1C/p57 expression in human
colorectal carcinoma. Acta Pharmacol Sin. 32:375–384. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Callegari E, Elamin BK, Giannone F, et al:
Liver tumorigenicity promoted by microRNA-221 in a mouse transgenic
model. Hepatology. 56:1025–1033. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Fornari F, Gramantieri L, Ferracin M, et
al: MiR-221 controls CDKN1C/p57 and CDKN1B/p27 expression in human
hepatocellular carcinoma. Oncogene. 27:5651–5661. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Gramantieri L, Fornari F, Ferracin M, et
al: MicroRNA-221 targets Bmf in hepatocellular carcinoma and
correlates with tumor multifocality. Clin Cancer Res. 15:5073–5081.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Lewis BP, Shih IH, Jones-Rhoades MW,
Bartel DP and Burge CB: Prediction of mammalian microRNA targets.
Cell. 115:787–798. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
John B, Enright AJ, Aravin A, Tuschl T,
Sander C and Marks DS: Human MicroRNA targets. PLoS Biol.
2:e3632004. View Article : Google Scholar
|
|
30
|
Sethupathy P, Corda B and Hatzigeorgiou
AG: TarBase: a comprehensive database of experimentally supported
animal microRNA targets. RNA. 12:192–197. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Jiang Q, Wang Y, Hao Y, et al:
miR2Disease: a manually curated database for microRNA deregulation
in human disease. Nucleic Acids Res. 37:D98–D104. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Landt SG, Marinov GK, Kundaje A, et al:
ChIP-seq guidelines and practices of the ENCODE and modENCODE
consortia. Genome Res. 22:1813–1831. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Shannon P, Markiel A, Ozier O, et al:
Cytoscape: a software environment for integrated models of
biomolecular interaction networks. Genome Res. 13:2498–2504. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Scherr M, Venturini L, Battmer K, et al:
Lentivirus-mediated antagomir expression for specific inhibition of
miRNA function. Nucleic Acids Res. 35:e1492007. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Scherr M, Battmer K, Ganser A and Eder M:
Modulation of gene expression by lentiviral-mediated delivery of
small interfering RNA. Cell Cycle. 2:251–257. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Naldini L, Blömer U, Gallay P, et al: In
vivo gene delivery and stable transduction of nondividing cells by
a lentiviral vector. Science. 272:263–267. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
D’Costa J, Mansfield SG and Humeau LM:
Lentiviral vectors in clinical trials: current status. Curr Opin
Mol Ther. 11:554–564. 2009.
|
|
38
|
Tili E, Michaille JJ, Gandhi V, Plunkett
W, Sampath D and Calin GA: miRNAs and their potential for use
against cancer and other diseases. Future Oncol. 3:521–537. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Hobert O: Gene regulation by transcription
factors and microRNAs. Science. 319:1785–1786. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Re A, Corá D, Taverna D and Caselle M:
Genome-wide survey of microRNA-transcription factor feed-forward
regulatory circuits in human. Mol Biosyst. 5:854–867. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Zeng L, Yu J, Huang T, et al: Differential
combinatorial regulatory network analysis related to venous
metastasis of hepatocellular carcinoma. BMC Genomics. 13(Suppl 8):
S142012. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Guo AY, Sun J, Jia P and Zhao Z: A novel
microRNA and transcription factor mediated regulatory network in
schizophrenia. BMC Syst Biol. 4:102010. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Zimonjic DB and Popescu NC: Role of DLC1
tumor suppressor gene and MYC oncogene in pathogenesis of human
hepatocellular carcinoma: Potential prospects for combined targeted
therapeutics (Review). Int J Oncol. 41:393–406. 2012.
|
|
44
|
Jeffers JR, Parganas E, Lee Y, et al: Puma
is an essential mediator of p53-dependent and -independent
apoptotic pathways. Cancer Cell. 4:321–328. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Zhang C, Zhang J, Zhang A, et al: PUMA is
a novel target of miR-221/222 in human epithelial cancers. Int J
Oncol. 37:1621–1626. 2010.PubMed/NCBI
|
|
46
|
Zhang CZ, Zhang JX, Zhang AL, et al:
MiR-221 and miR-222 target PUMA to induce cell survival in
glioblastoma. Mol Cancer. 9:2292010. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Kim I, Moon SO, Koh KN, et al: Molecular
cloning, expression, and characterization of angiopoietin-related
protein. Angiopoietin-related protein induces endothelial cell
sprouting. J Biol Chem. 274:26523–26528. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Kikuchi R, Tsuda H, Kozaki K, et al:
Frequent inactivation of a putative tumor suppressor,
angiopoietin-like protein 2, in ovarian cancer. Cancer Res.
68:5067–5075. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Feng SY, Dong CG, Wu WK, Wang XJ, Qiao J
and Shao JF: Lentiviral expression of anti-microRNAs targeting
miR-27a inhibits proliferation and invasiveness of U87 glioma
cells. Mol Med Rep. 6:275–281. 2012.PubMed/NCBI
|
|
50
|
Park JK, Kogure T, Nuovo GJ, et al:
miR-221 silencing blocks hepatocellular carcinoma and promotes
survival. Cancer Res. 71:7608–7616. 2011. View Article : Google Scholar : PubMed/NCBI
|
